Abstract: This application provides techniques comprising creating a main thread and at least two task threads; determining, by the main thread, a target task thread based on a data packet corresponding to a data transmission task in response to detecting the data transmission task associated with a client device, and sending the data packet to the target task thread, where the target task thread is any one of the at least two task threads; and receiving, by the target task thread, the data packet sent by the main thread, determining, based on the data packet, a first file descriptor corresponding to the client device, and communicating with the client device by using the first file descriptor to perform data transmission.

Abstract: Embodiments of the present application provide a display device and a display terminal. By arranging a back plate layer with a black light-shielding function, the back plate layer and a buffer and light-shielding layer are combined as one. The back plate includes a first back plate, and the first back plate is directly attached to a rigid supporting layer. The buffer and light-shielding layer is not required. As such, a thickness of the display device can be reduced, so that the display device is lighter and thinner.

Abstract: A method for checking a medium-term and long-term maintenance plan of a power grid. A predicted load value and one or more historical load values of a power grid are acquired and clustered through a clustering algorithm, and a historical moment at which a historical load value is in a same cluster as the predicted load value and has a largest load value is selected as a target historical moment. A power grid operation mode model at the target historical moment is acquired, and the power grid operation mode model is updated according to the maintenance plan and open loop point information by using a full wiring approach to obtain a future-state power grid operation mode model. Ground state power flow data of the power grid are calculated based on the operation mode model, and safety check is carried out according to a preset ground state power flow limit.

Abstract: The present disclosure discloses an intelligent screening algorithm and automatic upgrading system for congenital heart diseases of newborns based on big data. The key point of the technical solution is as follows: The intelligent screening algorithm and automatic upgrading system includes a heart sound data module, a heart sound data processing module, a blood oxygen data module, a blood oxygen data processing module, a network upgrading module, a database, an intelligent analysis module and a congenital heart disease evaluation module; the heart sound data module is configured to acquire various data of heart sounds of a newborn for centralized processing; and the heart sound data processing module is configured to process the data in the heart sound data module and extract heart sound feature parameters.

Abstract: A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.

Abstract: A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.